Shanghai Junshi Biosciences Co Ltd (688180) - Net Assets
Based on the latest financial reports, Shanghai Junshi Biosciences Co Ltd (688180) has net assets worth CN¥6.22 Billion CNY (≈ $910.73 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥12.38 Billion ≈ $1.81 Billion USD) and total liabilities (CN¥6.16 Billion ≈ $901.19 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Shanghai Junshi Biosciences Co Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.22 Billion |
| % of Total Assets | 50.26% |
| Annual Growth Rate | 30.97% |
| 5-Year Change | -25.3% |
| 10-Year Change | 452.43% |
| Growth Volatility | 64.47 |
Shanghai Junshi Biosciences Co Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Shanghai Junshi Biosciences Co Ltd's net assets have evolved over time, based on quarterly financial data. See 688180 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shanghai Junshi Biosciences Co Ltd (2014–2025)
The table below shows the annual net assets of Shanghai Junshi Biosciences Co Ltd from 2014 to 2025. For live valuation and market cap data, see Shanghai Junshi Biosciences Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.22 Billion ≈ $910.73 Million |
+4.60% |
| 2024-12-31 | CN¥5.95 Billion ≈ $870.71 Million |
-18.72% |
| 2023-12-31 | CN¥7.32 Billion ≈ $1.07 Billion |
-25.26% |
| 2022-12-31 | CN¥9.79 Billion ≈ $1.43 Billion |
+17.55% |
| 2021-12-31 | CN¥8.33 Billion ≈ $1.22 Billion |
+42.64% |
| 2020-12-31 | CN¥5.84 Billion ≈ $854.76 Million |
+95.46% |
| 2019-12-31 | CN¥2.99 Billion ≈ $437.31 Million |
-10.02% |
| 2018-12-31 | CN¥3.32 Billion ≈ $485.99 Million |
+196.71% |
| 2017-12-31 | CN¥1.12 Billion ≈ $163.79 Million |
-0.65% |
| 2016-12-31 | CN¥1.13 Billion ≈ $164.86 Million |
+83.42% |
| 2015-12-31 | CN¥614.22 Million ≈ $89.88 Million |
+92.02% |
| 2014-12-31 | CN¥319.87 Million ≈ $46.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Junshi Biosciences Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1118476459300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥1.03 Billion | 17.03% |
| Other Comprehensive Income | CN¥-39.78 Million | -0.66% |
| Other Components | CN¥16.26 Billion | 269.63% |
| Total Equity | CN¥6.03 Billion | 100.00% |
Shanghai Junshi Biosciences Co Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Junshi Biosciences Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Hope Corporation Ltd
AU:NHC
|
$3.34 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
$3.34 Billion |
|
Zhejiang Taotao Vehicles Co. Ltd. A
SHE:301345
|
$3.34 Billion |
|
PT Trimegah Bangun Persada Tbk
JK:NCKL
|
$3.34 Billion |
|
Multistrada Arah Sarana Tbk
JK:MASA
|
$3.34 Billion |
|
Sino-Platinum Metals Co Ltd
SHG:600459
|
$3.33 Billion |
|
Fermi Inc.
NASDAQ:FRMI
|
$3.33 Billion |
|
Pacific Securities Co Ltd
SHG:601099
|
$3.33 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Junshi Biosciences Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,878,551,000 to 6,030,434,432, a change of 151,883,432 (2.6%).
- Net loss of 875,174,329 reduced equity.
- New share issuances of 939,583,000 increased equity.
- Other comprehensive income increased equity by 22,044,259.
- Other factors increased equity by 65,430,502.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-875.17 Million | -14.51% |
| Share Issuances | CN¥939.58 Million | +15.58% |
| Other Comprehensive Income | CN¥22.04 Million | +0.37% |
| Other Changes | CN¥65.43 Million | +1.09% |
| Total Change | CN¥- | 2.58% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Junshi Biosciences Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.96x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 20.30x to 4.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥1.47 | CN¥29.78 | x |
| 2015-12-31 | CN¥2.72 | CN¥29.78 | x |
| 2016-12-31 | CN¥2.21 | CN¥29.78 | x |
| 2017-12-31 | CN¥1.93 | CN¥29.78 | x |
| 2018-12-31 | CN¥5.52 | CN¥29.78 | x |
| 2019-12-31 | CN¥3.84 | CN¥29.78 | x |
| 2020-12-31 | CN¥7.11 | CN¥29.78 | x |
| 2021-12-31 | CN¥8.94 | CN¥29.78 | x |
| 2022-12-31 | CN¥10.36 | CN¥29.78 | x |
| 2023-12-31 | CN¥7.27 | CN¥29.78 | x |
| 2024-12-31 | CN¥5.97 | CN¥29.78 | x |
| 2025-12-31 | CN¥6.00 | CN¥29.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Junshi Biosciences Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -35.03%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 2.05x
- Recent ROE (-14.51%) is above the historical average (-19.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -8.01% | -435.27% | 0.02x | 1.06x | CN¥-56.78 Million |
| 2015 | -9.55% | -2008.12% | 0.00x | 1.03x | CN¥-118.70 Million |
| 2016 | -11.62% | -3487.36% | 0.00x | 1.02x | CN¥-243.78 Million |
| 2017 | -28.63% | -27948.08% | 0.00x | 1.09x | CN¥-432.89 Million |
| 2018 | -21.56% | -76703.85% | 0.00x | 1.28x | CN¥-1.05 Billion |
| 2019 | -25.01% | -96.43% | 0.18x | 1.48x | CN¥-1.05 Billion |
| 2020 | -28.57% | -104.62% | 0.20x | 1.37x | CN¥-2.25 Billion |
| 2021 | -9.06% | -17.91% | 0.36x | 1.39x | CN¥-1.52 Billion |
| 2022 | -25.11% | -164.16% | 0.12x | 1.32x | CN¥-3.34 Billion |
| 2023 | -31.93% | -151.97% | 0.13x | 1.59x | CN¥-3.00 Billion |
| 2024 | -21.79% | -65.75% | 0.18x | 1.84x | CN¥-1.87 Billion |
| 2025 | -14.51% | -35.03% | 0.20x | 2.05x | CN¥-1.48 Billion |
Industry Comparison
This section compares Shanghai Junshi Biosciences Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,515,802,056
- Average return on equity (ROE) among peers: 9.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Junshi Biosciences Co Ltd (688180) | CN¥6.22 Billion | -8.01% | 0.99x | $3.34 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $105.51 Million | 6.20% | 2.16x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $7.92 Billion | 9.41% | 0.17x | $1.63 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $396.00 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $915.76 Million | -0.65% | 0.06x | $483.61 Million |
| Chengzhi Shareholding Co Ltd (000990) | $839.58 Million | 6.67% | 0.90x | $1.61 Billion |
| Hualan Biological EngineeringInc (002007) | $1.14 Billion | 16.37% | 0.10x | $3.45 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $914.64 Million | 16.73% | 0.74x | $1.10 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $4.65 Billion |
| Baolingbao Biology Co Ltd (002286) | $760.53 Million | 7.33% | 0.46x | $512.90 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.26 Billion | 16.10% | 0.32x | $1.71 Billion |
About Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more